Application of control of sodium ferulate on CXCL1 in preventing and controlling atherosclerosis

A technology of atherosclerosis and sodium ferulate, applied in the field of medicine, can solve the problems of less research on the effect of atherosclerosis and failure to study changes in gene expression, so as to achieve good cell growth and restore structure and function , to reduce the effect of facilitation

Inactive Publication Date: 2015-01-28
NANYANG MEDICAL COLLEGE
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the past, the research on CXCL1 focused on its effect on tumors, but less on its role in atherosclerosis
[0008] Traditional research methods focus on the role of SF in r

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of control of sodium ferulate on CXCL1 in preventing and controlling atherosclerosis
  • Application of control of sodium ferulate on CXCL1 in preventing and controlling atherosclerosis
  • Application of control of sodium ferulate on CXCL1 in preventing and controlling atherosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1: A certain concentration of SF can promote the proliferation of HUVEC

[0029] 1 Experimental material

[0030] 1.1 Experimental drugs

[0031] SF: purchased from Sigma Company in the United States.

[0032] 1.2 Experimental subjects

[0033] HUVEC: Human umbilical vein endothelial cell (HUVEC) strain CRL-1730 was purchased from ATCC Company.

[0034] 1.3 Reagents

[0035] 3-(4,5-Dimethylthiazole-2)-2,5-diphenyltetrazolium bromide (thiazole blue, MTT) was purchased from Sigma Company in the United States; dimethyl sulfoxide (DMSO) was purchased from the United States Sigma company; oxidized low-density lipoprotein (Ox-LDL) was purchased from Beijing Union Sanyou Technology Development Co., Ltd.; RPMI-1640 medium and fetal bovine serum were purchased from Hangzhou Sijiqing Bioengineering Materials Co., Ltd.; trypsin was purchased from Sigma, USA .

[0036] 1.4 Instruments

[0037] Carbon dioxide incubator was purchased from SHEL-LAB Company in the United...

Embodiment 2

[0054] Example 2: Antagonistic effect of SF on endothelial cell proliferation induced by Ox-LDL

[0055] 1 Experimental material

[0056] 1.1 Experimental drugs

[0057] SF: purchased from Sigma Company in the United States.

[0058] 1.2 Experimental subjects

[0059] HUVEC: Same as Example 1.

[0060] 1.3 Reagents

[0061] 3-(4,5-Dimethylthiazole-2)-2,5-diphenyltetrazolium bromide (thiazole blue, MTT) was purchased from Sigma Company in the United States; dimethyl sulfoxide (DMSO) was purchased from the United States Sigma company; oxidized low-density lipoprotein (Ox-LDL) was purchased from Beijing Union Sanyou Technology Development Co., Ltd.; RPMI-1640 medium and fetal bovine serum were purchased from Hangzhou Sijiqing Bioengineering Materials Co., Ltd.; trypsin was purchased from Sigma, USA .

[0062] 1.4 Instruments

[0063] Same as Example 1.

[0064] 2 Experimental methods:

[0065] 2.1 Culture of HUVEC cells

[0066] Same as Example 1.

[0067] 2.2 Grouping...

Embodiment 3

[0079] Example 3: Effect of SF on gene expression profiles of Ox-LDL-induced HUVECs

[0080] 1 Experimental material

[0081] 1.1 Experimental drugs

[0082] SF: Same as Example 1.

[0083] 1.2 Experimental subjects

[0084] HUVEC: Same as Example 1.

[0085] 1.3 Reagents

[0086] Oxidized low-density lipoprotein (Ox-LDL) was purchased from Peking Union Medical College Sanyou Technology Development Co., Ltd.; dimethyl sulfoxide (DMSO) was purchased from Sigma Company in the United States; oxidized low-density lipoprotein (Ox-LDL) was purchased from Peking Union Medical College Sanyou Technology Development Co., Ltd.; RPMI-1640 medium and fetal bovine serum were purchased from Hangzhou Sijiqing Bioengineering Materials Co., Ltd.; trypsin was purchased from Sigma, USA TRIZOL reagent was purchased from Shanghai Bioengineering Company; RNA Clean-up Kit was purchased from MN Company ;Gene chip 22K Human Genome Array from CapitalBio Co., Ltd.; Jingxin ? cRNA amplification lab...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses applications of sodium ferulate and expression of CXCL1 genes controlled by sodium ferulate in a mechanism for preventing and controlling atherosclerosis, and relates to a protective effect of sodium ferulate on a human umbilical vein endothelial cell (HUVEC) strain damaged by oxidized low-density lipoprotein (Ox-LDL), and discusses an action mechanism. Human umbilical vein endothelial cells are used to carry out experiments, influences of sodium ferulate on proliferation, migration and apoptosis of HUVEC treated by the oxidized low-density lipoprotein are determined by MTT, scratch test, flow cytometry and confocal microscopy; total RNA of the cells are extracted; marked hybrid experiments are carried out by using a CapitalBio whole-genome chip; differential genes are screened out by analyzing differential expression genes through clustering analysis, GO function and enrichment degree and pathway association degree, so that a gene expression spectrum can be obtained; and transcription and translation of the expressed differential genes in the HUVEC are detected by adopting a real-time quantitative PCR method. The results demonstrate that sodium ferulate can regulate CXCL1 gene expression downwards and has an obvious protective effect on the HUVEC damaged by Ox-LDL.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of a traditional Chinese medicine sodium ferulate on the regulation of CXCL1 gene in preventing and treating atherosclerosis. Background technique [0002] The prevalence of atherosclerosis has been on the rise for more than 100 years, and worldwide, atherosclerotic thrombosis accounts for 52% of all deaths, far exceeding the second leading cause of death. Tumors (24%) have become a veritable number one killer of death. Atherosclerosis is a systemic disease that can lead to dysfunction of major organs in the body, such as the heart, brain, kidneys, and even limbs, which seriously affects the quality of life of patients, and also brings a heavy burden to families and social economy. Therefore, it is very necessary to find high-efficiency and low-toxic drugs to prevent and treat atherosclerosis. [0003] The pathogenesis of atherosclerosis is very complex and has...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/192A61P9/10
CPCA61K31/192
Inventor 张东献陶俊良满永宏李巍薛士鹏张东意毕勇毅
Owner NANYANG MEDICAL COLLEGE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap